

Cathal Coyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8708433/publications.pdf>

Version: 2024-02-01

11
papers

105
citations

1684188

5
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

138
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192210886.	2.1	3
2	Alginates for Protection Against <sc>Pepsinâ€Acid</sc> Induced Aerodigestive Epithelial Barrier Disruption. <i>Laryngoscope</i> , 2022, 132, 2327-2334.	2.0	4
3	Editorial: simultaneous, prolonged monitoring of the acid pocket and oesophageal reflux. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 398-399.	3.7	0
4	Duration of adhesion of swallowed alginates to distal oesophageal mucosa: implications for topical therapy of oesophageal diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 442-448.	3.7	11
5	<p>Clinically Meaningful Difference for the Infant Gastroesophageal Questionnaire Revised version (I-GERQ-R): A Quantitative Synthesis</p>. <i>Patient Related Outcome Measures</i> , 2020, Volume 11, 87-93.	1.2	5
6	Randomised clinical trial: the effectiveness of Gaviscon Advance vs nonâ€alginate antacid in suppression of acid pocket and postâ€prandial reflux in obese individuals after lateâ€night supper. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1014-1021.	3.7	11
7	Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginateâ€antacid formulation (Gaviscon Double Action). <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 430-438.	2.0	2
8	Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginateâ€antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 86-93.	1.6	18
9	Sustained proton pump inhibitor deprescribing among dyspeptic patients in general practice: a return to self-management through a programme of education and alginate rescue therapy. A prospective interventional study. <i>BJGP Open</i> , 2019, 3, bjgpopen19X101651.	1.8	16
10	Randomised clinical trial: addition of alginateâ€antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1524-1533.	3.7	35
11	Editorial: refractory <sc>GERD</sc>â€good drug, wrong patients? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 204-205.	3.7	0